5-HT2C and GABAB receptors influence handling-induced convulsion severity in chromosome 4 congenic and DBA/2J background strain mice.
Progress towards elucidating the underlying genetic variation for susceptibility to complex central nervous system (CNS) hyperexcitability states has just begun. Genetic mapping analyses suggest that a gene(s) on mid-chromosome 4 has pleiotropic effects on multiple CNS hyperexcitability states in mice, including alcohol and barbiturate withdrawal and convulsions elicited by chemical and audiogenic stimuli. We recently identified Mpdz within this chromosomal region as a gene that influences alcohol and barbiturate withdrawal convulsions. Mpdz encodes the multi-PDZ domain protein (MPDZ). Currently, there is limited information available about the mechanism by which MPDZ influences drug withdrawal and/or other CNS hyperexcitability states, but may involve its interaction with 5-HT2C and/or GABAB receptors. One of the most useful tools we have developed thus far is a congenic strain that possesses a segment of chromosome 4 from the C57BL/6J (donor) mouse strain superimposed on a genetic background that is >99% from the DBA/2J strain. The introduced segment spans the Mpdz gene. Here, we demonstrate that handling-induced convulsions are less severe in congenic vs. background strain mice in response to either a 5-HT2C receptor antagonist (SB242084) or a GABAB receptor agonist (baclofen), but not a GABAA receptor channel blocker (pentylenetetrazol). These data suggest that allelic variation in Mpdz, or a linked gene, influences SB242084- and baclofen-enhanced convulsions. Our results are consistent with the hypothesis that Mpdz's effects on CNS hyperexcitability, including alcohol and barbiturate withdrawal, involve MPDZ interaction with 5-HT2C and/or GABAB receptors. However, additional genes reside within the congenic interval and may also influence CNS hyperexcitability.
Reilly
Matthew T
MT
Department of Behavioral Neuroscience and Portland Alcohol Research Center, Veterans Affairs Medical Center and Oregon Health & Science University, Portland, Oregon 97239, USA.
Milner
Lauren C
LC
Shirley
Renee L
RL
Crabbe
John C
JC
Buck
Kari J
KJ
D000818:Animals; D001921:Brain / Q000378:metabolism / Q000503:physiopathology; D001923:Brain Chemistry / Q000235:genetics; D002352:Carrier Proteins / Q000235:genetics* / Q000378:metabolism; D002874:Chromosome Mapping; D033481:Chromosomes, Mammalian / Q000235:genetics; D004827:Epilepsy / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D018755:GABA Agonists / Q000494:pharmacology; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006234:Handling, Psychological; D008297:Male; D008565:Membrane Proteins; D051379:Mice; D020297:Mice, Congenic; D008811:Mice, Inbred DBA; D008818:Mice, Neurologic Mutants; D044405:Receptor, Serotonin, 5-HT2C / Q000378:metabolism*; D018080:Receptors, GABA-B / Q000378:metabolism*; D012640:Seizures / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D012702:Serotonin Antagonists / Q000494:pharmacology; D013375:Substance Withdrawal Syndrome / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology
D002352:Carrier Proteins; D018755:GABA Agonists; D008565:Membrane Proteins; C491750:Mpdz protein, mouse; D044405:Receptor, Serotonin, 5-HT2C; D018080:Receptors, GABA-B; D012702:Serotonin Antagonists